Travere Therapeutics has received the US Food and Drug Administration (FDA) full approval for Filspari (sparsentan) to reduce ...
The clearance of Filspari in a condition known as FSGS ends a winding regulatory journey and unlocks a revenue opportunity ...
With the path to blockbusterland now in sight, Travere Therapeutics is ready to hit the ground running after Monday’s ...
Travere Therapeutics (TVTX) stock and Ligand Pharmaceuticals (LGND) stock gain on FDA label expansion for Filspari. Read more ...
Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare ...
The FDA has greenlit Travere Therapeutics’ Filspari as the only available treatment for focal segmental glomerulosclerosis ...
16h
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is ...
Travere Therapeutics shares surged in premarket trading after the company received regulatory approval in the U.S. for its rare kidney-disorder treatment. Shares trading in premarket rose 37% to ...
Full FDA approval establishes sparsentan as the first approved therapy for FSGS, addressing a longstanding reliance on ...
Travere Therapeutics (TVTX) stock rallied 44% after FDA approved FILSPARI for FSGS treatment, targeting over 30,000 U.S.
The U.S. Food and Drug Administration (USFDA) has approved the expanded use of Travere Therapeutics' drug to treat a rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results